Capricor Advances For FDA Advisory Committee Meeting In July Amid Strong Long-Term Deramiocel Data

Capricor Therapeutics said the FDA's Cellular, Tissue, and Gene Therapies Advisory Committee will meet on July 29, 2026 to discuss the company. The notice is procedurally important for the regulatory review process, but the article provides no decision, recommendation, or substantive outcome. Overall impact appears limited and primarily event-driven.

Analysis

Capricor Therapeutics said the FDA's Cellular, Tissue, and Gene Therapies Advisory Committee will meet on July 29, 2026 to discuss the company. The notice is procedurally important for the regulatory review process, but the article provides no decision, recommendation, or substantive outcome. Overall impact appears limited and primarily event-driven.